GLUE
Monte Rosa Therapeutics, Inc. [GLUE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GLUE Stock Summary
Top GLUE Correlated Resources
GLUE
Top 10 Correlated ETFs
GLUE
Top 10 Correlated Stocks
GLUE
In the News
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events:
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcoming investor conferences:
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the following upcoming investor conferences:
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 5:15 p.m. ET on Tuesday, January 11, 2022.
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein Degradation Summit on Wednesday, Oct. 27 at 11:45 a.m. ET. The presentation, titled, “Molecular Glue Degraders: From Serendipity to Rational Design,” will showcase the capabilities of Monte Rosa's QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform and its impact on expanding target space.
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical data for the company's GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer has been selected for a late-breaking poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 7-10.
Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of second quarter initial public offering additions, effective Sept. 20, 2021. The stock will also be automatically added to the appropriate growth and value indexes.
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, and Ajim Tamboli, CFA, Chief Financial Officer, are scheduled to participate in a virtual fireside chat at 2 p.m. ET on Wednesday, Sept. 15 at the Morgan Stanley 19th Annual Global Healthcare Conference.
GLUE Financial details
GLUE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | |
| Net income per share | -0.69 | -3.22 | -6.64 | |
| Operating cash flow per share | -0.55 | -2.07 | -5.33 | |
| Free cash flow per share | -0.68 | -2.37 | -6.2 | |
| Cash per share | 0.54 | 3.74 | 31.05 | |
| Book value per share | -1.09 | -4.37 | 31.18 | |
| Tangible book value per share | -1.09 | -4.37 | 31.18 | |
| Share holders equity per share | -1.09 | -4.37 | 31.18 | |
| Interest debt per share | 0.07 | 0 | 0 | |
| Market cap | 236.04M | 236.04M | 227.57M | |
| Enterprise value | 230.79M | 194.34M | -118.5M | |
| P/E ratio | -30.5 | -6.58 | -3.08 | |
| Price to sales ratio | 0 | 0 | 0 | |
| POCF ratio | -38.24 | -10.24 | -3.83 | |
| PFCF ratio | -31.23 | -8.93 | -3.29 | |
| P/B Ratio | -19.43 | -4.84 | 0.65 | |
| PTB ratio | -19.43 | -4.84 | 0.65 | |
| EV to sales | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -30.1 | -5.5 | 1.65 | |
| EV to operating cash flow | -37.39 | -8.43 | 2 | |
| EV to free cash flow | -30.54 | -7.35 | 1.72 | |
| Earnings yield | -0.03 | -0.15 | -0.32 | |
| Free cash flow yield | -0.03 | -0.11 | -0.3 | |
| Debt to equity | -1.91 | -2.01 | 0.05 | |
| Debt to assets | 2.1 | 1.99 | 0.05 | |
| Net debt to EBITDA | 0.68 | 1.18 | 4.82 | |
| Current ratio | 2.27 | 1.49 | 20.96 | |
| Interest coverage | -7.99K | 0 | 0 | |
| Income quality | 0.8 | 0.64 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.22 | 0.15 | 0.16 | |
| Capex to revenue | 0 | 0 | 0 | |
| Capex to depreciation | -19.24 | -6.31 | -4.56 | |
| Stock based compensation to revenue | 0 | 0 | 0 | |
| Graham number | 4.13 | 17.8 | 68.24 | |
| ROIC | 1.95 | 0.68 | 0.22 | |
| Return on tangible assets | -0.7 | -0.73 | -0.2 | |
| Graham Net | -1.55 | -5.06 | 29.37 | |
| Working capital | 5.47M | 14.32M | 332.03M | |
| Tangible asset value | -12.15M | -48.73M | 347.52M | |
| Net current asset value | -13.48M | -54.52M | 329.85M | |
| Invested capital | -0.06 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | |
| Average payables | 0 | 5.13M | 6.81M | |
| Average inventory | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | |
| ROE | 0.64 | 0.74 | -0.21 | |
| Capex per share | -0.12 | -0.3 | -0.87 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.43 | -0.51 | -0.51 | -0.57 | -0.58 | |
| Operating cash flow per share | -0.39 | -0.31 | -0.59 | -0.44 | -0.44 | |
| Free cash flow per share | -0.43 | -0.37 | -0.62 | -0.49 | -0.47 | |
| Cash per share | 7.98 | 7.53 | 6.81 | 6.3 | 5.82 | |
| Book value per share | 8.03 | 7.56 | 6.99 | 6.47 | 6.23 | |
| Tangible book value per share | 8.03 | 7.56 | 6.99 | 6.47 | 6.23 | |
| Share holders equity per share | 8.03 | 7.56 | 6.99 | 6.47 | 6.23 | |
| Interest debt per share | 0 | 0 | 0.15 | 1.06 | 1 | |
| Market cap | 1.02B | 939.07M | 653.27M | 451.28M | 381.8M | |
| Enterprise value | 657.58M | 593M | 521.95M | 396.38M | 315.07M | |
| P/E ratio | -12.91 | -10.02 | -6.82 | -4.26 | -3.49 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -57.58 | -66.26 | -23.84 | -22.01 | -18.53 | |
| PFCF ratio | -52.41 | -54.5 | -22.46 | -19.58 | -17.35 | |
| P/B Ratio | 2.77 | 2.7 | 2 | 1.49 | 1.31 | |
| PTB ratio | 2.77 | 2.7 | 2 | 1.49 | 1.31 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -34.15 | -26.2 | -22.66 | -15.89 | -12.46 | |
| EV to operating cash flow | -36.95 | -41.84 | -19.05 | -19.33 | -15.29 | |
| EV to free cash flow | -33.64 | -34.41 | -17.94 | -17.19 | -14.32 | |
| Earnings yield | -0.02 | -0.02 | -0.04 | -0.06 | -0.07 | |
| Free cash flow yield | -0.02 | -0.02 | -0.04 | -0.05 | -0.06 | |
| Debt to equity | 0.04 | 0.05 | 0.06 | 0.21 | 0.23 | |
| Debt to assets | 0.04 | 0.05 | 0.06 | 0.17 | 0.19 | |
| Net debt to EBITDA | 19.06 | 15.29 | 5.7 | 2.2 | 2.64 | |
| Current ratio | 29.08 | 20.96 | 25.65 | 20.11 | 13.55 | |
| Interest coverage | 0 | 0 | -163.1 | -43.36 | -28.45 | |
| Income quality | 0.9 | 0.6 | 1.15 | 0.77 | 0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.1 | 0.22 | 0.06 | 0.12 | 0.07 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -3.02 | -3.78 | -2.24 | -2.87 | -1.36 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.83 | 9.31 | 8.99 | 9.09 | 9.05 | |
| ROIC | 0.06 | 0.07 | -0.37 | -0.18 | -0.23 | |
| Return on tangible assets | -0.05 | -0.06 | -0.07 | -0.07 | -0.08 | |
| Graham Net | 7.66 | 7.12 | 6.37 | 4.95 | 4.68 | |
| Working capital | 357.78M | 332.03M | 307.88M | 282.27M | 273.45M | |
| Tangible asset value | 369.31M | 347.52M | 325.88M | 302.05M | 291.09M | |
| Net current asset value | 355.78M | 329.85M | 300.24M | 234.04M | 228.72M | |
| Invested capital | 0 | 0 | 0.02 | 0.16 | 0.16 | |
| Average receivables | 0 | 0 | 0 | 0 | 8.78M | |
| Average payables | 5.5M | 5.04M | 5.53M | 4.4M | 7.02M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.05 | -0.07 | -0.07 | -0.09 | -0.09 | |
| Capex per share | -0.04 | -0.07 | -0.04 | -0.05 | -0.03 |
GLUE Frequently Asked Questions
What is Monte Rosa Therapeutics, Inc. stock symbol ?
Monte Rosa Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol GLUE
What is Monte Rosa Therapeutics, Inc. stock quote today ?
Monte Rosa Therapeutics, Inc. stock price is $6.78 today.
Is Monte Rosa Therapeutics, Inc. stock public?
Yes, Monte Rosa Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 140.58K
- Market Capitalization 349.44M
- Employee 118
- CEO Dr. Markus Warmuth M.D.
- Headquarters Boston,MA,US
- IPO Date 2021-06-24
-
Website
https://www.monterosatx.com 
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
